Equities analysts expect that Five Prime Therapeutics Inc (NASDAQ:FPRX) will report ($1.31) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have issued estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.48) and the highest is ($1.10). Five Prime Therapeutics posted earnings of ($1.04) per share during the same quarter last year, which would indicate a negative year over year growth rate of 26%. The firm is expected to issue its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Five Prime Therapeutics will report full-year earnings of ($4.32) per share for the current year, with EPS estimates ranging from ($4.47) to ($4.12). For the next year, analysts anticipate that the business will post earnings of ($5.26) per share, with EPS estimates ranging from ($6.58) to ($4.27). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.15) by ($0.22). The firm had revenue of $5.77 million during the quarter, compared to analyst estimates of $7.45 million. Five Prime Therapeutics had a negative return on equity of 41.52% and a negative net margin of 221.67%.
Shares of NASDAQ:FPRX opened at $12.19 on Wednesday. The company has a market capitalization of $457.51 million, a PE ratio of -2.27 and a beta of 3.34. Five Prime Therapeutics has a 1 year low of $10.35 and a 1 year high of $24.82.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its stake in Five Prime Therapeutics by 61.1% during the second quarter. Citadel Advisors LLC now owns 147,047 shares of the biotechnology company’s stock worth $2,325,000 after buying an additional 55,783 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Five Prime Therapeutics by 14.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 175,895 shares of the biotechnology company’s stock worth $2,781,000 after buying an additional 22,572 shares during the last quarter. Aquilo Capital Management LLC acquired a new position in Five Prime Therapeutics during the second quarter worth $1,025,000. ARK Investment Management LLC boosted its stake in Five Prime Therapeutics by 165.9% during the second quarter. ARK Investment Management LLC now owns 183,094 shares of the biotechnology company’s stock worth $2,895,000 after buying an additional 114,240 shares during the last quarter. Finally, Algert Global LLC acquired a new position in Five Prime Therapeutics during the second quarter worth $476,000. 85.99% of the stock is currently owned by institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.
Recommended Story: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.